Vnitr Lek 2022, 68(5):342-344

Entresto (sakubitril-valsartan) získalo prestižní mezinárodní Galénovu cenu za nejlepší farmaceutický produkt pro rok 2022

Filip Málek
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

Published: August 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Entresto (sakubitril-valsartan) získalo prestižní mezinárodní Galénovu cenu za nejlepší farmaceutický produkt pro rok 2022. Vnitr Lek. 2022;68(5):342-344.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021, doi:10.1093/eurheartj/ehab368 Go to original source... Go to PubMed...
    2. McMurray JJ, Packer M, Desai AS et al. Angiotensin neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. Go to original source... Go to PubMed...
    3. Wachter R, Senni M, Belohlavek J et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998-1007. Go to original source... Go to PubMed...
    4. Velazquez EJ, Morrow DA, DeVore AD et al for PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-548. Go to original source... Go to PubMed...
    5. Januzzi JI, Prescott MF, Butler J et al. For PROVE-HF Investigators Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Faction JAMA. 2019 Sep 2:1-11. doi: 10.1001/jama.2019.12821 Go to original source... Go to PubMed...
    6. Desai AS, Solomon SD, Shah AM et al. for the EVALUATE-HF Investigators Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial JAMA. 2019 Sep 2:1-10. doi: 10.1001/jama.2019.12843 Go to original source... Go to PubMed...
    7. Diego C, Gonzáles-Torres L, Nunez JM et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices Heart Rhythm 2018;15:395-402. Go to original source... Go to PubMed...
    8. Martens P, Nuyens D, Rivero-Ayerza M et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin. Res. Cardiol. 2019, doi: 10.1007/s00392-019-01440-y Go to original source... Go to PubMed...
    9. Chandra A, Lewis EF, Claggett BL et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. A Secondary Analysis of the PARADIGM-HF Trial JAMA Cardiology 2018, doi:10.1001/jamacardio.2018.0398 Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.